BACKGROUND AND PURPOSE: To assess the efficacy and safety of ramelteon, a selective
MT1/MT2 receptor agonist, for chronic insomnia treatment. PATIENTS AND METHODS …

Objective: To assess the efficacy and safety of ramelteon, a selective melatonin MT1/MT2-
receptor agonist, for insomnia treatment in older adults. Methods: In a randomized, 9‑week …

BACKGROUND AND PURPOSE: To evaluate the efficacy, safety, and dose response of
Ramelteon, a novel highly selective MT1/MT2 receptor agonist, in patients with chronic …

Objective: To evaluate efficacy and safety of ramelteon (MT1/MT2-receptor agonist) in
subjects with chronic primary insomnia. Methods: Randomized, multicenter, double-blind …

Abstract Study Objectives: Long-duration (≥ 6 months) polysomnographic studies of
insomnia medications are lacking. This study evaluated the long-term efficacy of ramelteon …

Objective: Evaluate the efficacy of ramelteon, an MT1/MT2-receptor agonist, for the treatment
of transient insomnia in healthy adults. Design: Randomized, double-blind, placebo …

BACKGROUND:: Insomnia is a common sleep disorder with a significant potential for
deleterious effects on activities of daily living, productivity, and overall quality of life …

Ramelteon (Rozerem™) is the first melatonin receptor agonist to be approved for the
treatment of insomnia; it is not classified as a controlled substance. In patients with chronic …

Ramelteon is the first selective melatonin receptor agonist and currently is approved in the
United States and Japan for the treatment of insomnia. Our meta-analysis assessed the …

An estimated one‐third of the general population is affected by insomnia, and this number is
increasing due to more stressful working conditions and the progressive aging of society …